Vaborbactam
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vaborbactam: From Carbapenem-Resistant Bacterial Infections to Osteoarthritis
One-Sentence Summary
Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor, used together with meropenem against infections caused by carbapenemase-producing bacteria. The TxGNN model predicts it may be effective for osteoarthritis, but there are currently no clinical trials and no publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (the licensed product is an injectable powder for infusion) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.52% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, vaborbactam is a beta-lactamase inhibitor that protects meropenem from serine carbapenemases such as KPC. It is an antibacterial adjunct and has no known activity on joint cartilage or on inflammatory or degenerative pathways.
No plausible mechanistic link to osteoarthritis was identified. The high TxGNN score reflects proximity in a knowledge graph, not biological or clinical evidence. The other top predictions (osteoarthritis susceptibility, rheumatoid arthritis, gout, and several rare skeletal dysplasias) show the same pattern: all are model predictions with no supporting trials or literature, and they appear to arise from shared graph neighbours among musculoskeletal disease nodes.
This prediction should be treated as a computational hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17224P | VABOREM Powder for Concentrate for Solution for Infusion 1G/1G | Injection, powder, for solution | Not stated in the licence record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based only on a knowledge-graph score. There are no clinical trials or publications, and no plausible mechanism links an antibacterial beta-lactamase inhibitor to osteoarthritis. The evidence level is L5.
To proceed, the following is needed:
- Retrieve the HSA package insert and review its warnings and contraindications (a blocking gap for safety screening)
- Obtain mechanism of action data from DrugBank
- Provide a biological rationale and preclinical evidence linking vaborbactam to osteoarthritis pathways
- Carry out a systematic literature and trial registry search to confirm that no relevant studies exist
- Assess route compatibility, since the only licensed form is an intravenous infusion and osteoarthritis treatment may require a different route
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.